0
Reviews |

Aerosolized Magnesium Sulfate for Acute Asthma*: A Systematic Review

Maurice Blitz, MD; Sandra Blitz, MSc; Rodney Hughes, MBChB; Barry Diner, MD; Richard Beasley, MD; Jennifer Knopp, BScN, MN; Brian H. Rowe, MD, MSc, FCCP
Author and Funding Information

*From the Division of General Surgery (Dr. M. Blitz) and Departments of Emergency Medicine (Ms. S. Blitz and Dr. Rowe) and Family Medicine (Ms. Knopp), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; the Medical Research Institute of New Zealand (Drs. Hughes and Beasely), Wellington, NZ; and the Department of Emergency Medicine (Dr. Diner), Emory University, Atlanta, GA.

Correspondence to: Brian H, Rowe, MD, MSc, FCCP, Department of Emergency Medicine, 1G1.43 WMC, 8440–112 Street, Edmonton, AB, Canada T6G 2B7; e-mail: brian.rowe@ualberta.ca



Chest. 2005;128(1):337-344. doi:10.1378/chest.128.1.337
Text Size: A A A
Published online

Background: The use of MgSO4 is one of numerous treatment options available during exacerbations of asthma. While the efficacy of therapy with IV MgSO4 has been demonstrated, little is known about inhaled MgSO4.

Objectives: A systematic review of the literature was performed to examine the effect of inhaled MgSO4 in the treatment of patients with asthma exacerbations in the emergency department.

Methods: Randomized controlled trials were eligible for inclusion and were identified from the Cochrane Airways Group “Asthma and Wheez*” register, which consists of a combined search of the EMBASE, CENTRAL, MEDLINE, and CINAHL databases and the manual searching of 20 key respiratory journals. Reference lists of published studies were searched, and a review of the gray literature was also performed. Studies were included if patients had been treated with nebulized MgSO4 alone or in combination with β2-agonists and were compared to the use of β2-agonists alone or with an inactive control substance. Trial selection, data extraction, and methodological quality were assessed by two independent reviewers. The results from fixed-effects models are presented as standardized mean differences (SMDs) for pulmonary functions and the relative risks (RRs) for hospital admission. Both are displayed with their 95% confidence intervals (CIs).

Results: Six trials involving 296 patients were included. There was a significant difference in pulmonary function between patients whose treatments included nebulized MgSO4 and those whose did not (SMD, 0.30; 95% CI, 0.05 to 0.55; five studies). There was a trend toward a reduced number of hospitalizations in patients whose treatments included nebulized MgSO4 (RR, 0.67; 95% CI, 0.41 to 1.09; four studies). Subgroup analyses demonstrated that lung function improvement was similar in adult patients and in those patients who received nebulized MgSO4 in addition to a β2-agonist.

Conclusions: The use of nebulized MgSO4, particularly in addition to a β2-agonist, in the treatment of an acute asthma exacerbation appears to produce benefits with respect to improved pulmonary function and may reduce the number of hospital admissions.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543